despit revenue miss manag bottom line result ep
come ahead consensu due lower expens vs
tax rate vs howev ep guidanc cut significantli
issu cite management primarili relat
gener rx busi final decid separ gener
unit unclear point truli unlock sharehold valu
chca perform dampen declin anim chci show
steadi improv rx pharma hamper price eros lack new
launch turnaround rev flagship us consum busi
chca declin loss higher margin pet care product place drag
divis despit tight sg manag oper margin declin reflect
higher cog unfavor product mix prgo chci unit continu improv
post second consecut weak quarter rev y/i reflect gener price eros
lack new product launch fact soft genericslarg price pressur
delay g-proair scopolaminerepres mgt lower guidanc
revers prior stanc separ rx pharma busi
truli enhanc sharehold valu management board recent conclud
rigor analysi busi decis separ gener divis sometim
either tax effici separ sharehold spin sale merger
view move would benefit busi via increas focu
seem run counter prior commentari meaning synergi
two busi term product development/regulatori suppli chain
manufactur end management believ consum gener busi
suffici differ term distribut portfolio manag alreadi
begun process separ market distribut function importantli
new ceo uwe roehrhoff state meaning impact dis-synergi
advantag outweigh potenti separ issu post intern analysi
understand theori stand-alone consum busi potenti garner
improv valuat metric arent convinc yet hard believ arent
synergi particularli manufactur side moreov prgo gener unit
typic commod busi fact far higher margin vs either
consum divis
deploy buyback dividend ytd seemingli
ampl dri powder busi develop strong cash flow gener
oper continu disciplin approach capit
alloc co deploy share repurchas paid dividend
debt matur due next year management believ
well posit capit opportun present
management demur discuss extern strategi call note wait
septemb webcast see seem like good bet return
consum tuck in success employ year past
management lay lt strateg plan month follow review valu
creation roadmap call management highlight element valu creation
roadmap includ plan particip select rx over-the-counter switch
leverag expertis suppli chain regulatory/r capabl etc illustr
nasonex transact management plan host webcast septemb discuss
detail addit find increas oper effici plan drive
organ new over-the-counter categori expand categori new brand offer well
inorgan growth consum busi
pleas see analyst certif import disclosur inform inform regard statu non-u analyst page report
chart quarterli varianc tabl except per share data
page
pleas see import disclosur inform page report
changetot cost interest/oth incom ep fulli outstand fulli revenu changeconsum healthcar healthcar pharma
perrigo compani plc lead global healthcar supplier develop manufactur distribut over-the-count over-the-counter
prescript rx pharmaceut nutrit product activ pharmaceut ingredi api
pt remain vs modestli lower ep estimate vs base risk gener price
david steinberg certifi view express research report accur reflect person view subject secur
subject compani also certifi part compens directli indirectli relat specif recommend
view express research report
edward chung certifi view express research report accur reflect person view subject secur
subject compani also certifi part compens directli indirectli relat specif recommend
view express research report
anthoni baldor certifi view express research report accur reflect person view subject secur
subject compani also certifi part compens directli indirectli relat specif recommend
view express research report
case jefferi employe analyst respons coverag financi instrument discuss report receiv
compens base part overal perform firm includ invest bank incom seek updat research
appropri variou regul may prevent us asid certain industri report publish period basi larg major
report publish irregular interv appropri analyst judgement
articl articl
explan jefferi rate
buy describ secur expect provid total return price appreci plu yield within period
hold describ secur expect provid total return price appreci plu yield plu minu within period
under-perform describ secur expect provid total return price appreci plu yield minu less within
expect total return price appreci plu yield buy rate secur averag secur price consist
within period compani typic volatil overal stock market hold rate secur averag
secur price consist expect total return price appreci plu yield plu minu within period
under-perform rate secur averag secur price consist expect total return price appreci plu yield minu
less within period
nr invest rate price target temporarili suspend suspens complianc applic regul and/
jefferi polici
cs coverag suspend jefferi suspend coverag compani
nc cover jefferi cover compani
restrict describ issuer conjunct jefferi engag certain transact compani polici applic secur
regul prohibit certain type commun includ invest recommend
monitor describ secur whose compani fundament financi monitor financi project opinion
invest merit compani provid
jefferi methodolog assign rate may includ follow market capit matur growth/valu volatil expect total
return next month price target base sever methodolog may includ restrict analys market
p/fcf premium discount /averag group ev/ebitda premium discount /averag group price-to-earnings sum part net asset valu dividend return
return equiti roe next month
page
pleas see import disclosur inform page report
jefferi franchis pick includ stock select among best stock idea equiti analyst month period stock select
base fundament analysi may take account factor analyst convict differenti analysi favor risk/reward
ratio invest theme jefferi analyst recommend jefferi franchis pick includ buy rate stock number
vari depend analyst recommend inclus stock ad new opportun aris remov reason
inclus chang stock met desir return longer rate buy and/or trigger stop loss stock day volatil
bottom quartil stock continu stop loss remaind stop franchis pick intend
repres recommend portfolio stock sector base may note believ pick fall within invest style
growth valu
risk may imped achiev price target
report prepar gener circul provid invest recommend specif individu investor
financi instrument discuss report may suitabl investor investor must make invest decis base
upon specif invest object financi situat util financi advisor deem necessari past perform
financi instrument recommend report taken indic guarante futur result price valu
incom financi instrument mention report rise well fall may affect chang econom financi
polit factor financi instrument denomin currenc investor home currenc chang exchang rate may
advers affect price valu incom deriv financi instrument describ report addit investor secur
adr whose valu affect currenc underli secur effect assum currenc risk
note box rate price target histori chart repres action past three year analyst initi
compani made chang rate price target compani discontinu coverag compani
import disclosur inform compani recommend report pleas visit websit http //javatar bluematrix com/sellside/
